ABT
the council passes — AVOIDABBOTT LABORATORIES·Healthcare
The quality and the price don't line up.
60/100C
Price at last run$95.90as of Jul 8, 2026
healthcare!
Hard veto — the risk officer blocks this
One or more rules are designed to stop a buy outright — no matter how cheap or how loved the name. Here, at least one fired:
- Valuation BLOCK: no margin of safety (price >= fair value)
Conviction
none
No conviction — the council would not put money behind this at today's price.
Fat operating margins18% operating margin — pricing power / a real moat hint.
Generates real cash4.4% free-cash-flow yield — profits you can actually bank.
Clean balance sheetLow leverage (debt/equity 0.00).
Catalystnone yet
✕Why not
The honest case against — what most tools hideRisk officer vetoBlocked: Valuation BLOCK: no margin of safety (price >= fair value).
Main riskno obvious red flag
Demanding valuationRuns 41% above our patience price.
What keeps us out
- Paying up here — we'd want a better entry price.
- Growth slowing while the multiple stays rich.
Patience price & distance
as of Jul 8, 2026 runGets interesting at
≈$64
−33% from today's $96
The patience price is where value discipline would let the council in — deliberately strict: we'd rather miss ten winners than own one loser.
The price currently runs 41% above our patience price. A target is an estimate, not a promise — markets can stay wrong for a long time, and the estimate can be wrong too.
Margin of safety by scenario
Bear
-76%
if things go wrong
Bull
-25%
if things go right
Each column is the discount to that scenario's fair value. The bear column is the one that matters most — a wide bear-case cushion is what lets the council own a name through a bad year.
Catalyst
insider buying
A catalyst is a plausible reason the gap could close — never a certainty.